MX2019014489A - Programa de dosificacion para tesetaxel y capecitabina. - Google Patents
Programa de dosificacion para tesetaxel y capecitabina.Info
- Publication number
- MX2019014489A MX2019014489A MX2019014489A MX2019014489A MX2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A MX 2019014489 A MX2019014489 A MX 2019014489A
- Authority
- MX
- Mexico
- Prior art keywords
- capecitabine
- tesetaxel
- dosing schedule
- patient
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762514483P | 2017-06-02 | 2017-06-02 | |
| PCT/US2018/035653 WO2018223029A1 (en) | 2017-06-02 | 2018-06-01 | Dosing schedule for tesetaxel and capecitabine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019014489A true MX2019014489A (es) | 2020-08-17 |
Family
ID=64455637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019014489A MX2019014489A (es) | 2017-06-02 | 2018-06-01 | Programa de dosificacion para tesetaxel y capecitabina. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200179427A1 (https=) |
| EP (1) | EP3630091A4 (https=) |
| JP (1) | JP2020522568A (https=) |
| KR (1) | KR20200014880A (https=) |
| CN (1) | CN111032035A (https=) |
| AU (1) | AU2018275122A1 (https=) |
| BR (1) | BR112019025164A2 (https=) |
| CA (1) | CA3065783A1 (https=) |
| EA (1) | EA201992852A1 (https=) |
| IL (1) | IL270973A (https=) |
| MA (1) | MA50039A (https=) |
| MX (1) | MX2019014489A (https=) |
| TW (1) | TW201902473A (https=) |
| WO (1) | WO2018223029A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA53929A (fr) * | 2018-10-17 | 2021-08-25 | Odonate Therapeutics Inc | Méthodes de traitement de tumeurs du système nerveux central au moyen de tesetaxel |
| WO2021034335A1 (en) * | 2019-08-16 | 2021-02-25 | Odonate Therapeutics, Inc. | Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016168451A1 (en) * | 2015-04-14 | 2016-10-20 | Merrimack Pharmaceuticals, Inc. | Compositions for improving the pharmacokinetics and therapeutic index of cancer treatment |
-
2018
- 2018-06-01 BR BR112019025164-2A patent/BR112019025164A2/pt not_active Application Discontinuation
- 2018-06-01 MA MA050039A patent/MA50039A/fr unknown
- 2018-06-01 WO PCT/US2018/035653 patent/WO2018223029A1/en not_active Ceased
- 2018-06-01 US US16/617,697 patent/US20200179427A1/en not_active Abandoned
- 2018-06-01 TW TW107119026A patent/TW201902473A/zh unknown
- 2018-06-01 CN CN201880041477.0A patent/CN111032035A/zh active Pending
- 2018-06-01 KR KR1020207000023A patent/KR20200014880A/ko not_active Ceased
- 2018-06-01 JP JP2020516788A patent/JP2020522568A/ja not_active Withdrawn
- 2018-06-01 CA CA3065783A patent/CA3065783A1/en not_active Abandoned
- 2018-06-01 AU AU2018275122A patent/AU2018275122A1/en not_active Abandoned
- 2018-06-01 EA EA201992852A patent/EA201992852A1/ru unknown
- 2018-06-01 MX MX2019014489A patent/MX2019014489A/es unknown
- 2018-06-01 EP EP18808779.5A patent/EP3630091A4/en not_active Withdrawn
-
2019
- 2019-11-27 IL IL270973A patent/IL270973A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018275122A1 (en) | 2019-12-19 |
| EA201992852A1 (ru) | 2020-03-27 |
| TW201902473A (zh) | 2019-01-16 |
| KR20200014880A (ko) | 2020-02-11 |
| MA50039A (fr) | 2020-07-08 |
| WO2018223029A1 (en) | 2018-12-06 |
| IL270973A (en) | 2020-01-30 |
| US20200179427A1 (en) | 2020-06-11 |
| CA3065783A1 (en) | 2018-12-06 |
| JP2020522568A (ja) | 2020-07-30 |
| CN111032035A (zh) | 2020-04-17 |
| EP3630091A4 (en) | 2021-03-10 |
| BR112019025164A2 (pt) | 2020-06-16 |
| EP3630091A1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020006668A (es) | Anticuerpos para lilrb2. | |
| MX2021004881A (es) | Combinacion de palbociclib y rad1901 para usarse en el tratamiento de cancer de mama en un sujeto con cancer positivo a receptor de estrogeno. | |
| MX2019003938A (es) | Compuestos espirociclicos. | |
| GEP20217331B (en) | Anti-tigit antibodies | |
| MX2020011783A (es) | Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer. | |
| PH12016500137B1 (en) | Afucosylated anti-fgfr2iiib antibodies | |
| MX2016007282A (es) | Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico. | |
| MX375221B (es) | Composiciones que comprenden anticuerpos anti-molécula de adhesión celular relacionada con antígeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cáncer. | |
| MX370597B (es) | Uso de un anticuerpo biespecífico para dll3 y cd3 en el tratamiento y profilaxis de cáncer. | |
| PH12016501411A1 (en) | Bifunctional cytotoxic agents | |
| PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
| MX2023012451A (es) | Composiciones para usarse en el tratamiento de una enfermedad autoinmune y cancer. | |
| NZ631701A (en) | Apoptosis-including agents for the treatment of cancer and immune and autoimmune diseases | |
| MY178726A (en) | Combination therapy of an afucosylated cd20 antibody with a btk inhibitor | |
| MX377729B (es) | Métodos para tratamiento del melanoma. | |
| MX2016014007A (es) | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. | |
| MX2016004678A (es) | Composiciones para el tratamiento del cancer. | |
| MX2017016353A (es) | Metodos para tratar canceres de mama metastasicos o localmente avanzados con antagonistas de union al eje de pd-1 y taxanos. | |
| GEP20217317B (en) | Combination therapy for the treatment of cancer | |
| MX2019002925A (es) | Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer. | |
| MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
| EA201792612A1 (ru) | 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot | |
| MX379622B (es) | Compuestos espirociclicos | |
| MX2017014436A (es) | Compuestos biciclicos. | |
| MX2020000636A (es) | Proteinas sinteticas y usos terapeuticos de las mismas. |